Clinical trials: Liver Transplant Rejection
Liver Transplant Rejection, Immune System Suppression
Conversion of Maintenance Prograf to Envarsus in Liver Transplant Recipients
Prograf and Envarsus are two different formulations of Tacrolimus which is used as an immunosuppressant in liver transplant (LT) patients.
- Trial name
- NCT05655273
- Testing
- Prograf, Envarsus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Liver Transplantation
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant.
- Trial name
- NCT00118742
- Testing
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine
- Where
- 46 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Hoffmann-La Roche
Liver Transplant Rejection
TRU-IMMUNO: Optimizing Liver Immunosuppression
This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide…
- Trial name
- NCT05335551
- Testing
- Patients monitored with TruGraf and TRAC Liver testing
- Volunteers
- 130 people
- Sponsor
- Transplant Genomics, Inc.
Liver Transplantation (LT), Immuno-suppression
Immune Biomarkers for Predicting Complications After Liver Transplantation
This multicenter prospective observational study will evaluate immune biomarkers in adults undergoing liver transplantation. The study aims to describe how immune markers change before and after transplantation and to assess…
- Conditions
- Liver Transplantation (LT), Immuno-suppression, Biomarkers / Blood, Rejection
- Trial name
- NCT07875595
- Testing
- Immune Biomarker Assessment
- Where
- 3 sites in Argentina
- Volunteers
- 60 people
- Sponsor
- Hospital Italiano de Buenos Aires
Immunosuppression
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease…
- Trial name
- NCT07206277
- Testing
- Immunosuppression reduction
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Liver Disease
Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation
Assessment of the role of tissue C4d complement fragments in liver biopsy as a new marker for differentiating between acute rejection and Hepatitis C (HCV) recurrence in recipients post living donor liver transplantation (LDLT)…
- Trial name
- NCT02209675
- Testing
- liver biopsy
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Ain Shams University
Liver Transplant Rejection
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
This was a multicenter, open-label, active-controlled study to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of two CFZ533 maintenance doses in de novo liver transplant recipients.
- Trial name
- CONTRAIL I (NCT03781414)
- Testing
- CFZ533, Tacrolimus - MMF - corticosteroids
- Where
- 29 sites in United States, Argentina and 8 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant Recipients, Liver Transplantation
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
The primary objective of this study is to assess the efficacy of immunosuppression withdrawal (ISW) in pediatric liver transplant (tx) recipients.
- Conditions
- Liver Transplant Recipients, Liver Transplantation, Immunosuppression
- Trial name
- iWITH (NCT01638559)
- Testing
- Immunosuppression withdrawal
- Where
- 12 sites in United States, Canada
- Volunteers
- 161 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression After Liver Transplantation
Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation
The best period for the conversion from Prograf (tacrolimus administered twice daily) to Advagraf (once-daily prolonged-release tacrolimus) remains unknown.
- Trial name
- Conversion (NCT02105155)
- Testing
- Conversion at day 7 ± 3 Prograf® to Advagraf®, Conversion at day 90±5 Prograf® to Advagraf®
- Where
- France
- Volunteers
- 90 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Transplant Rejection, Immunosuppressant Adverse Reaction
Long-term Benefit of MPA in Liver Transplantation
MPA drugs are antiproliferative immunosuppressants and are widely used in solid organ transplantation. MPA drugs do not affect the recipient's kidney function and do not cause metabolic abnormalities and other problems.
- Trial name
- NCT05707520
- Testing
- enteric-coated mycophenolate (MPAs), None MPA
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Rejection; Transplant, Liver, Liver Failure
Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients
The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal.
- Conditions
- Rejection; Transplant, Liver, Liver Failure, Liver Diseases
- Trial name
- LIBERATE (NCT05234190)
- Testing
- QEL-001
- Where
- 10 sites in Belgium, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- Quell Therapeutics Limited
Rejection Acute Hepatic, Transplant; Failure, Liver
Single-center Prospective Study of Non-invasive Methods for the Diagnosis of Postoperative Complications in Liver Transplant Recipients
A lot of different early and late complications may occur after liver transplantation. They could be related to surgical procedure, to infectious diseases or immuno-mediated diseases (acute cellular rejection, ACR).
- Conditions
- Rejection Acute Hepatic, Transplant; Failure, Liver, Liver Dysfunction
- Trial name
- ElastOLT (NCT05793203)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Heart Failure, Liver Fibrosis
Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
Magnetic resonance elastography is a novel non-invasive MRI technique to obtain stiffness of soft tissues such as liver, heart, kidneys, etc.
- Conditions
- Heart Failure, Liver Fibrosis, Cardiac Transplant Rejection, Aortic Aneurysms
- Trial name
- MRE (NCT01757730)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Arunark Kolipaka
Graft Rejection, Heart Transplantation
Diagnostic Validity of [18F]FSPG PET for the Assessment of Acute Rejection After Heart or Liver Transplantation
The a series of clinical studies of [18F]FSPG PET/CT showed that [18F]FSPG is safe and promising PET tracer for detecting inflammation with favorable biodistribution and pharmacokinetics in patients.
- Conditions
- Graft Rejection, Heart Transplantation, Liver Transplantation
- Trial name
- NCT04488094
- Testing
- [18F]FSPG
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Asan Medical Center
Chronic Rejection of Liver Transplant
Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for…
- Trial name
- Treg (NCT01624077)
- Testing
- Regulatory T cells
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University
Evidence of Liver Transplantation, Rejection
Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation
This open-label clinical trial will evaluate the safety and efficacy of Alemtuzumab (Campath, Bayer Corp., Pittsburgh) in children (0-17) and adults (18-25) receiving intestinal transplant.
- Conditions
- Evidence of Liver Transplantation, Rejection, ALEMTUZUMAB
- Trial name
- NCT01208337
- Testing
- Alemtuzumab
- Volunteers
- 23 people
- Sponsor
- University of Pittsburgh
Autoimmune Diseases, Inflammation
Prospective Study of White Blood Cells
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
- Conditions
- Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver
- Trial name
- NCT04838171
- Testing
- White blood cell and blood collection
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Quell Therapeutics Limited
Heart Transplantation, Kidney Transplantation
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection.
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
- Trial name
- NCT00531921
- Where
- 5 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cirrhosis, Hepatitis C
Adult-to-Adult Living Donor Liver Transplantation Study
There are two principal purposes of this study: 1) to determine whether it is more beneficial for a liver transplant recipient candidate to pursue a living donor liver transplant (LDLT) or wait for a deceased donor liver…
- Conditions
- Cirrhosis, Hepatitis C, Hepatocellular Carcinoma
- Trial name
- A2ALL-1 (NCT00096733)
- Where
- 9 sites in United States
- Volunteers
- 2,470 people
- Sponsor
- Arbor Research Collaborative for Health